Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Update

by · The Cerbat Gem

Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Free Report) was the target of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 162,900 shares, a growth of 74.0% from the October 15th total of 93,600 shares. Based on an average daily volume of 221,600 shares, the short-interest ratio is currently 0.7 days. Currently, 1.3% of the shares of the company are sold short.

Chemomab Therapeutics Price Performance

Shares of NASDAQ:CMMB remained flat at $1.74 during midday trading on Thursday. 209,964 shares of the stock were exchanged, compared to its average volume of 186,728. The firm has a market capitalization of $24.99 million, a price-to-earnings ratio of -1.53 and a beta of 0.53. Chemomab Therapeutics has a 1 year low of $0.42 and a 1 year high of $2.55. The firm has a fifty day moving average price of $1.57 and a two-hundred day moving average price of $1.26.

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last posted its earnings results on Wednesday, August 21st. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.06). During the same period last year, the firm earned ($0.72) EPS. Equities analysts predict that Chemomab Therapeutics will post -0.9 EPS for the current year.

About Chemomab Therapeutics

(Get Free Report)

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Read More